Topotecan: An evolving option in the treatment of relapsed small cell lung cancer

References

• ArdizzoniATopotecan in the treatment of recurrent small cell lung cancer: an updateOncologist20049Suppl 641315616145
   PubMed Web of Science ®Google Scholar
• ArdizzoniAHansenHDombernowskyPTopotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative GroupJ Clin Oncol199715209069164222
   PubMed Web of Science ®Google Scholar
• ArdizzoniAManegoldCDebruyneCEuropean organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancerClin Cancer Res200391435012538462
   PubMed Web of Science ®Google Scholar
• ArmstrongDO’ReillySClinical Guidelines for Managing Topotecan-Related Hematologic ToxicityOncologist1998341010388079
   PubMedGoogle Scholar
• ArmstrongDKSpriggsDLevinJHematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysisOncologist2005106869416249347
   PubMed Web of Science ®Google Scholar
• ChristodoulouCKalofonosHPBriasoulisECombination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG)Cancer Chemother Pharmacol2006572071216028103
   PubMed Web of Science ®Google Scholar
• CiomborKKRocha LimaCMManagement of small cell lung cancerCurr Treat Options Oncol20067596816343369
   PubMedGoogle Scholar
• DepierreAvon PawelJHansKEvaluation of topotecan (HycamtinTM) in relapsed small cell lung cancer (SCLC). A multicentre phase II studyLung Cancer199718Suppl 1359268946
   PubMed Web of Science ®Google Scholar
• EckardtJGrallaRPalmerMCTopotecan (T) as second-line therapy in patients (Pts) with small cell lung cancer (SCLC): a phase II studyAnn Oncol19967Suppl 5107
   Google Scholar
• GarstJBullerRLaneSTopotecan in the treatment of elderly patients with relapsed small-cell lung cancerClin Lung Cancer20057190616354314
   PubMed Web of Science ®Google Scholar
• GarstJHerndonJEShafmanTA phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancerClin Druv Invest20062625766
   PubMed Web of Science ®Google Scholar
• HoCDaviewAMLaraPNSecond-line treatment for advanced-stage non-small cell lung cancer: current and future optionsClin Lung Cancer20067118s125s
   PubMed Web of Science ®Google Scholar
• HuberRMReckMGosseHEfficacy of a toxicity-adjusted topotecan therapy in recurrent small-cell lung cancerEur Respir J2006271183916481389
   PubMed Web of Science ®Google Scholar
• HurriaAKrisMGManagement of lung cancer in older adultsCA Cancer J Clin2003533254115224973
   PubMed Web of Science ®Google Scholar
• Hycamtin® (topotecan hydrochloride) for injection [prescribing information]2006Research Triangle Park, NCGlaxoSmithKline
   Google Scholar
• JemalASiegelRWardECancer statisticsCA Cancer J Clin2006561063016514137
   PubMed Web of Science ®Google Scholar
• KoschelRHuberRMGatzemeierUTopotecan in second-line treatment of small cell lung cancer reduced toxicity with individualized therapyLung Cancer20002042
   Google Scholar
• MaranzanoECrinoLPiroFLong-term results of induction chemotherapy followed by concurrent chemotherapy and thoracic irradiation in limited small cell lung cancerLung Cancer200237798512057871
   PubMed Web of Science ®Google Scholar
• MurhpyPBHainsworthJDSpigelDRTopotecan–single agent activity in a weekly intravenous (IV) schedule for first-line therapy in poor prognosis extensive stage small cell lung cancer (SCLC): a Minnie Pearl Cancer Research Network phase II trial [abstract]Proc Am Soc Clin Oncol20062418s Abstract 17000
   Web of Science ®Google Scholar
• OgawaraMNegoroSNishiwakiYPhase II study of topotecan (TOP) for relapsed small cell lung cancer (SCLC)Lung Cancer200029Suppl 140
   Google Scholar
• OkunoSHJettJRSmall cell lung cancer: current therapy and promising new regimensOncologist20027234812065796
   PubMed Web of Science ®Google Scholar
• Perez-SolerRGlissonBSLeeJSTreatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecanJ Clin Oncol1996142785908874340
   PubMed Web of Science ®Google Scholar
• RothenbergMLTopoisomerase I inhibitors: review and updateAnn Oncol19978837559358934
   PubMed Web of Science ®Google Scholar
• ShipleyDLHainsworthJDSpigelDRTopotecan: weekly intravenous (IV) schedule similar to standard 5-day IV schedule as second-line therapy for relapsed small cell lung cancer (SCLC) – a Minnie Pearl Cancer Research Network phase II trial [abstract]J Clin Oncol200624384s Abstract 7083
   Web of Science ®Google Scholar
• StathopoulosGPChristodoulouCStathopoulosJSecond-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II studyCancer Chemother Pharmacol20065779680016142488
   PubMed Web of Science ®Google Scholar
• TakedaKNegoroSSawaTA phase II study of topotecan in patients with relapsed small-cell lung cancerClin Lung Cancer20034224814624710
   PubMedGoogle Scholar
• TreatJHuangCHLaneSRTopotecan in the treatment of relapsed small cell lung cancer patients with poor performance statusOncologist200491738115047921
   PubMed Web of Science ®Google Scholar
• von PawelJGatzemeierUPujolJLPhase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancerJ Clin Oncol2001191743911251005
   PubMed Web of Science ®Google Scholar
• von PawelJSchillerJHShepherdFATopotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancerJ Clin Oncol1999176586710080612
   PubMed Web of Science ®Google Scholar